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Placebo by proxy
Clinicians’ and family members’ feelings and perceptions about a treatment may influence their
judgments about its effectiveness
David J Grelotti child and adolescent psychiatry fellow
1, Ted J Kaptchuk associate professor of
medicine
2
1Department of Psychiatry, Massachusetts General Hospital and McLean Hospital, Harvard Medical School, Boston, MA 02114, USA;
2Program in
Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
The effect of placebo on the patient and the patient’s
environment is often debated, but people other than the patient
may also feel better when a patient receives placebo treatment.
The anthropologist Claude Lévi-Strauss alluded to this when
he described how medical treatments, including those where
ritual alone provides the cure, occur in a social context and
convey a “sense of security” to the social group.
1
Cliniciansandfamilymembersmayhaveanemotionalresponse
to a patient’s treatment and think that the treatment is helping
the patient even in the absence of any direct physiological
benefit to the patient or indication from the patient that the
treatment is working. These feelings and perceptions may arise
when placebos, including “impure” placebos, such as active
drugs or operations that have no effect on the disease process,
areusedinclinicalpracticeandresearchsettings.Becausethese
feelings and perceptions are not accounted for in descriptions
oftheplaceboeffectandcanexistindependentlyofanyplacebo
effect on the patient, they can be described as placebo effects
by proxy, or placebo by proxy for short. Although placebo by
proxy has important implications, the phenomenon is
underappreciated and rarely discussed.
Placebo by proxy could be as ubiquitous as the placebo effect,
and in some situations placebo by proxy can dominate clinical
decisionmaking.Forexample,theparentsofachildwithaviral
upper respiratory illness may believe that the child needs
antibiotics,andparentalexpectationsorthedoctor’sperception
of parental expectations (or both) may influence prescribing
patterns.
2 3 Antibiotics are overprescribed in these situations
and function as impure placebos
4; the psychological benefit to
the parent, such as a relief from worry, represents placebo by
proxy.
In the absence of evidence to support long term use of
antipsychotics in patients with dementia and a history of
agitation,aggression,orpsychosis,
5 6placebobyproxymayhelp
to explain why clinicians often maintain their patients on these
drugs. In a controlled double blind study of discontinuation of
psychotropics in a sample of patients with dementia who were
takingthesedrugsbecauseofahistoryofagitation(67.3%were
taking antipsychotics), the authors found a lack of an effect of
psychotropics when they compared mean scores on behaviour
rating scales during the treatment and placebo phases of the
trial.
6 However, clinical workers were resistant to stopping
treatment because they had “a great deal of faith in the utility
of these drugs to control agitation in this population.”
6
Psychotropics functioned as impure placebos for many of these
patients, and the concern of clinicians that patients would
decompensate without these drugs provides another example
of placebo by proxy.
In addition to influencing clinical decision making, placebo by
proxycouldinfluenceestimationsoftreatmentoutcomeintrials,
especiallywhentheperceptionsofcliniciansorfamilymembers
are favoured over objective markers of patient response.
7 In
placebocontrolledclinicaltrialsofsecretintoreducesymptoms
ofautism,thepatient’sresponsetosecretinwasprimarilybased
on the opinions of parents, teachers, or clinicians (or a
combination thereof).
8 Ten randomised controlled trials and a
meta-analysis showed robust and consistent reductions in core
symptoms of autism as measured by standardised rating scales
in both the treatment and placebo groups, but no significant
differences were seen between the groups on these measures.
8 9
The robust response to placebo may have been influenced by
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EDITORIALSanecdotalreports,whichgeneratedpositivepressaboutsecretin
and gave rise to the need for clinical trials.
8 9 Perception or
misperception by parents may also partially explain a larger
placebo response in children than in adults participating in
clinical trials of treatment resistant epilepsy.
10
Placebobyproxymayalsoexplainfindingsfrommeta-analyses
whereimprovementmeasuredbyobserversismuchhigherthan
improvementreportedbypatients.Forexample,fordepression,
themeaneffectsizeofobserverratedimprovementis1.85(95%
confidence interval 1.69 to 2.01), compared with 0.67 (0.49 to
0.85) for patient reported improvement.
11 For irritable bowel
syndrome, the pooled placebo response rate for physician rated
improvement is 53.0%, compared with 37.4% for patient rated
improvement (P=0.005).
12
The different mechanisms that underlie the placebo effect are
likely to shape placebo by proxy also.
12 These processes may
include seeing other patients respond to the same drug,
associative learning such as conditioning, a supportive
physician-patient relationship, and reduced anxiety.
Placebo by proxy and the placebo effect may interact to create
positivechange.Forexample,ifcliniciansandfamilymembers
feel empowered and optimistic about a disease, the patient’s
environment can become less stressful and more supportive.
Cliniciansandfamilymembersmayreacttoplacebobysmiling
more,payingmoreattentiontothepatient,promotingtreatment
adherence, encouraging the patient to engage in new activities,
or creating other targets for behavioural change.
8 9 In this way,
placebo by proxy may elicit changes in the patient’s
psychosocial context that mediate the placebo effect.
Although placebo by proxy may enhance clinical outcomes, it
mightalsocauseharm.Iftreatmentrelateddecisionsareunduly
weighted towards providing a psychological benefit to people
other than the patient, the patient may not benefit from the
treatmentyetmaystillbeartherisks.Thetreatmentsmentioned
abovecostmoneyandarenotbenign:antibioticscausediarrhoea
and are associated with antibiotic resistance, antipsychotics are
associated with an increased risk of death in elderly patients
with dementia related psychosis, and secretin infusion may
result in a life threatening allergic reaction. Placebo by proxy
may create a false sense that a patient is getting better and
therebypreventmoreappropriatetreatment,
7 8oritmayproduce
changes in attitude and behaviour towards the patient that lead
to neglect. Placebo by proxy is probably more likely to cause
harm when decisions are made in the absence of clinical
evidence and when patients cannot make decisions for
themselves.
Treatment benefits could be maximised and harms mitigated if
placebobyproxyweretakenintoaccountwhenmakingclinical
decisions. For many of the above clinical situations, an
appreciation of placebo by proxy may prompt clinicians to
question attachments to treatment practices that are not
supported by evidence. Placebo by proxy could be used as a
potential clinical tool. For example, it may be possible to boost
the psychological benefit of a patient’s treatment by generating
appropriate enthusiasm for treatment among those involved in
the patient’s care. Because almost every treatment related
decision is shared and patients sometimes agree to treatment to
make their clinicians and family members happy, clinicians
should be aware of placebo by proxy when guiding clinical
decisions and evaluating treatment response.
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